Strides Pharma Science · NSE: STAR · BSE: 532531

Q3 FY22 results · Oct–Dec 2021

Strides Pharma Science reported revenue from operations of ₹794.39 crore (down 4.5% from Q3 FY21) and net loss of ₹126.66 crore for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY22	Q3 FY21	YoY	Q2 FY22	QoQ
Revenue from operations	794.39	832.02	−4.5%	721.47	+10.1%
Other income	10.19	13.20	−22.8%	22.21	−54.1%
Total income	804.58	845.23	−4.8%	743.68	+8.2%
Profit before share of associates & JVs and tax	(106.86)	72.85	Turned loss	(151.37)	Loss narrowed
Share of profit/(loss) of associates & JVs	(24.27)	(26.91)		(23.37)
Net profit for the period	(126.66)	35.16	Turned loss	(167.98)	Loss narrowed
Attributable to shareholders of the company	(121.67)	37.85	Turned loss	(162.56)	Loss narrowed
EPS, basic (₹)	(13.55)	4.22	Turned loss	(18.12)	Loss narrowed
Net margin (%)	-15.9	4.2		-23.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY22	Q3 FY21	YoY	Q2 FY22	QoQ
Revenue from operations	439.56	421.08	+4.4%	575.00	−23.6%
Other income	7.50	16.23	−53.8%	22.41	−66.5%
Total income	447.06	437.31	+2.2%	597.41	−25.2%
Profit before tax	(31.69)	27.36	Turned loss	24.28	Turned loss
Net profit for the period	(17.60)	20.49	Turned loss	18.52	Turned loss
EPS, basic (₹)	(1.96)	2.29	Turned loss	2.06	Turned loss
Net margin (%)	-4.0	4.9		3.2

Consolidated

Filed with BSE: 10 Feb 2022, 16:27 IST
Board meeting: 10 Feb 2022
Period: 01 Oct 2021 to 31 Dec 2021
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 10 Feb 2022, 16:27 IST
Board meeting: 10 Feb 2022
Period: 01 Oct 2021 to 31 Dec 2021
Review status: Unaudited
Source: XBRL filing on BSE